Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of Ionis Pharmaceuticals’s Ulefnersen Sodium?
Ulefnersen Sodium is an antisense oligonucleotide commercialized by Ionis Pharmaceuticals, with a leading Phase III program in Amyotrophic Lateral Sclerosis.
Pharmaceutical Technology13m
Risk adjusted net present value: What is the current valuation of Artiva Biotherapeutics’s GCC-4001?
GCC-4001 is a cell therapy commercialized by Artiva Biotherapeutics, with a leading Phase II program in B-Cell Non-Hodgkin Lymphoma.
Pharmaceutical Technology2m
Risk adjusted net present value: What is the current valuation of Neurocrine Biosciences’s NBI-1076986?
Neurocrine Biosciences (Neurocrine) is a biopharmaceutical company that discovers, develops, and markets neurological drugs. The company’s lead product Ingrezza, is a vesicular monoamine transporter 2 ...
Pharmaceutical Technology14m
Risk adjusted net present value: What is the current valuation of Keros Therapeutics’s Cibotercept?
Cibotercept is a fusion protein commercialized by Keros Therapeutics, with a leading Phase II program in Pulmonary Arterial Hypertension.
Pharmaceutical Technology31m
Risk adjusted net present value: What is the current valuation of Armata Pharmaceuticals’s APSA-02?
APSA-02 is a biologic commercialized by Armata Pharmaceuticals, with a leading Phase II program in Bacteremia.
Pharmaceutical Technology40m
Risk adjusted net present value: What is the current valuation of Intra-Cellular Therapies’s ITI-333?
ITI-333 is a small molecule commercialized by Intra-Cellular Therapies, with a leading Phase I program in Opium (Opioid) Addiction.
Pharmaceutical Technology1h
Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb’s Cendakimab?
Cendakimab is a monoclonal antibody commercialized by Bristol-Myers Squibb, with a leading Phase III program in Eosinophilic Esophagitis.
Pharmaceutical Technology34m
Risk adjusted net present value: What is the current valuation of AstraZeneca’s Eneboparatide?
Eneboparatide is a recombinant peptide commercialized by AstraZeneca, with a leading Phase III program in Hypoparathyroidism.
Pharmaceutical Technology49m
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Mazisotine?
Mazisotine is a small molecule commercialized by Eli Lilly and Co, with a leading Phase II program in Diabetic Neuropathic Pain.
Pharmaceutical Technology31m
Risk adjusted net present value: What is the current valuation of I-Mab’s Givastomig?
The revenue for Givastomig is expected to reach an annual total of $48 mn by 2040 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to ...
Pharmaceutical Technology41m
Risk adjusted net present value: What is the current valuation of UCB’s (Doxecitine + Doxribtimine)?
(Doxecitine + Doxribtimine) is a small molecule commercialized by UCB, with a leading Phase III program in Inherited Mitochondrial Disorders.